Response Profiles to High-concentration Capsaicin Desensitization in Patients With Peripheral Neuropathic Pain With or Without Allodynia: a Regional Multicenter Prospective Cohort

Peripheral Neuropathic Pain Clinical Trial

— CAPSICAURA  

Official title:

Response Profiles to High-concentration Capsaicin Desensitization in Patients With Peripheral Neuropathic Pain With or Without Allodynia: a Regional Multicenter Prospective Cohort

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05817591
• Other study ID #: 19-50
• Status: Recruiting
• Start date: December 14, 2023
• Est. completion date: June 15, 2026

Study information

• Verified date: December 2023
• Source: Centre Hospitalier Annecy Genevois
• Contact: Marion GHIDI
• Phone: +33450637031
• Email: drci.promotion[@]ch-annecygenevois.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prospective multicenter cohort to determine patient profiles (associated factors, including allodynia) with a better response to pain desensitization by capsaicin delivered in the form of a high concentration patch (8%), in a population of patients with peripheral neuropathic pain and followed up in a pain consultation in the Auvergne Rhône Alpes region.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: June 15, 2026
• Est. primary completion date: June 15, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient over 18 years of age on the day of inclusion

• Patient who has been informed and has not expressed opposition to participating in the study,

• Patient with peripheral neuropathic pain (whatever the etiology), defined by :

• "Neuropathic Pain 4" score ("DN4" score) = 4/10

• AND pain according to the numerical scale (EN) > 4/10,

• AND stable analgesic treatment for at least 1 month,

• AND with or without mechanical allodynia according to the Quantitative Sensory Testing (QST) : Brush test (dynamic), Von Frey test (static)

• AND with or without thermal allodynia to hot or cold as determined by a ROLLTEMP-II® (Rolltemp is a device designed for quick screening of temperature sensibility over large body areas).

• Patient responding to an indication of desensitization to high concentration capsaicin concentration and not presenting any contra-indication.

• Patient naïve of high concentration of Capsaicin on the concerned zone

• Patient understanding French

Non-inclusion Criteria:

• Patient with pain related to complex regional pain syndrome (criteria not meeting the indication for capsaicin)

• Patient with active cancer (underlying disease and treatments may modify pain perception),

• Patient receiving or having received in the last 3 months Botulinum toxin A on the concerned area (this treatment of neuropathic pain may modulate the effect of capsaicin and disturb the demonstration of causality),

• Patient with planned surgery within the next 12 months on the painful site (surgery may cause neuropathic damage and/or bias the pain assessment),

• Patient included in an interventional research protocol,

• Patient under guardianship or curators,

• Patient under legal protection

Exclusion Criteria:

None

Related Conditions & MeSH terms

• Hyperalgesia
• Neuralgia
• Peripheral Neuropathic Pain

Intervention

Other:
• Questionnaires
In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is > 4 Pain monitoring questionnaires will be completed by patients every 6 weeks : Neuropathic Pain Symptom Invetory (NPSI Score), Patients' Global Impression of Change (PGIC scale), Numerical pain scale

Locations

Country	Name	City	State
France	Centre Hospitalier Annecy Genevois	Annecy
France	Hospices Civils de Lyon, Hôpital Pierre Wertheimer	Bron
France	Centre Hospitalier Métropole Savoie	Chambéry
France	Centre Hospitalier Universitaire de Clermont-Ferrand	Clermont-Ferrand
France	Centre Hospitalier Universitaire Grenoble-Alpes	Grenoble
France	Centre Léon Bérard	Lyon
France	Hospices Civils de Lyon, Hôpital de la Croix Rousse	Lyon
France	Centre Hospitalier Universitaire de Saint-Etienne	Saint-Étienne
France	Clinique Mutualiste Chirurgicale de Saint Etienne	Saint-Étienne
France	Médipôle Lyon Villeurbanne	Villeurbanne

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Annecy Genevois

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Factors (profiles) associated with a better initial response to pain desensitization by capsaicin	A patient is a responder if he has a reduction in pain, as measured by a numerical pain scale, of at least 30% from baseline. The scale used is "EN - échelle numérique" in french, "NRS - Numerical Rating Scale" in english, between 0 and 10 (0 being the absence of pain and 10 the most intense pain).	12 months
Secondary	Proportion [95% Confidence Interval (CI)] of patients "responder at 30%" at 1.5 months after each consecutive patch (e.g. at M4.5 for a second patch applied at M3)		1.5 months after each consecutive patch
Secondary	Proportion [95% CI] of patients "initial responder" at 50%		12 months
Secondary	Distribution of Neuropathic Pain Symptom Inventory (NPSI) score values over time: at inclusion, 3 months, 6 months, 9 months,12 months, and between inclusion and the end of follow-up	The NPSI scale is composed of 12 questions (10 descriptive questions of symptoms and 2 to evaluate the frequency and duration of pain). The score for the descriptive questions is between 0 and 100 (0 being the absence of pain and 10 the most intense pain).	Each 3 months and over 12 months
Secondary	Distribution of NPSI subscores values (Q8, Q9, Q10) over time: at inclusion, 3 months, 6 months, 9 months,12 months, and between inclusion and the end of follow-up		Each 3 months and over 12 months
Secondary	Distribution of Patients' Global Impression of Change (PGIC) scale score values over time: at 1.5 months, 3 months, 4.5 months, 6 months, 7.5 months, 9 months,10.5 months, 12 months, and between inclusion and the end of follow-up	The Patients' Global Impression of Change (PGIC) scale describe the change (if any) in activity limitations, symptoms, emotions, and overall quality of life. It is between 1 and 7 (1 being no change or conditions has got worse, and 7 is a great deal better and a considerable improvement that as made all the difference).	Each 1.5 months and over 12 months
Secondary	In the subpopulation of patients with allodynia (dynamic mechanical or static or thermal): proportion [95% CI] of "responders" at 7.5 months		7.5 months
Secondary	In the subpopulation of initial responders at the 30% threshold: proportion [95% CI] of patients relapsing at 12 months, defined as pain scale (EN) > 4/10, indicating a new capsaicin patch		12 months
Secondary	Number of new initiation of analgesic treatment, defined by the addition of a molecule to the treatment given at the time of application of the first capsaicin patch		12 months
Secondary	Number of reduction of analgesic treatment, defined by the stop of a molecule compared to the treatment given at the time of the application of the first capsaicin patch		12 months